Immunotherapy for prostate cancer: an emerging treatment modality.
This article examines prostate cancer as a target for immunotherapy and investigates active immunotherapy for prostate cancer, combining conventional therapy with active immunotherapy, immune modulators (brakes and accelerators), and monoclonal antibodies.
Departments of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, 1650 Orleans Street CRB I #410, Baltimore, MD 21231, USA. cdrake@jhmi.edu
Charles G
CG
Drake
D004359:Drug Therapy, Combination; D006801:Humans; D007167:Immunotherapy; D008297:Male; D011471:Prostatic Neoplasms / Q000276:immunology* / Q000628:therapy*; D016896:Treatment Outcome